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Chronic heart failure is a complicated multifactorial disease with wide-spread social-economic consequences. In spite of the recent
development of new drugs and therapeutic strategies, CHF-related mortality and morbidity remain high. Recent evidence suggests
that changes in organs such as skeletal muscle and gut flora may play an important and independent role in CHF prognosis. This
paper illustrates these phenomena, proposing how to identify them and presenting current therapies which treat organs all too
often underestimated but which have a fundamental role in worsening CHF.
1. Introduction
Chronic heart failure (CHF) is a very common and multi-
factor syndrome. In spite of currently used therapies, it still
has high mortality and mobility [1]. Malnutrition, in partic-
ular with protein metabolism impairment and consequent
cachexia, has often been found inCHFpatients and correlates
closely with mortality [2]. Furthermore, we recently demon-
strated that CHF patients have important changes in both gut
flora and intestinal permeability, which influence systemic
inflammation and global metabolism by modifying nutrients
absorption and production of molecules fundamental for cell
life (authors’ unpublished data). These conditions are often
ignored or underestimated by most clinicians, although they
have been shown to increase morbidity, hospital stay, and
mortality risk independent of the primary cause of CHF.
This paper illustrates the clinical problems related to
malnutrition (basically, protein malnutrition) and gut flora
modification in CHF patients. We also look at some possibly
easily repeatable methods to identify these pathological
conditions and to try to care for them. In the wait for
genetic therapies and stem cells for CHF [3], we believe
that identifying and possibly curing proteinmalnutrition and
composition alteration and/or gut microbiota activity could
be an important step to improveCHFpatient care.Thiswould
avoid additional and independent clinical damage and allow
traditional therapies to work more efficiently.
2. Malnutrition
2.1. A Definition. Malnutrition is a general term that encom-
passes various forms of inadequate nutrition. It is mul-
tifactorial but is basically caused by the reduced balance
between body nutrient intake and needs. Qualitative and
quantitative malnutrition are often present in CHF and
protein malnutrition, leading to the disarrangement of both
visceral and muscular proteins. These conditions have been
extensively studied in CHF [2, 4].
Proteinmalnutrition can be estimated in patients bymea-
suring visceral protein (e.g., serum albumin concentrations)
and muscular wasting (e.g., armmuscle area). Indeed, serum
albumin level < 3.5 g/dL (without diseases interfering with
albumin metabolism, such as liver or renal insufficiency)
and muscular sarcopenia (<5th percentile of normal upper-
arm muscle area) are important markers of poor protein
nutritional status. This is because they can predict morbidity
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and mortality in CHF independent of the primary cause of
the disease [5, 6]. Recently, other simple nutritional assess-
ment tools, such as the Geriatric Nutritional Risk Index
(GNRI), which considers serum albumin and body mass
index (BMI), correlate with lower serum hemoglobin and
systemic inflammation (higher C-reactive protein) and have
been seen to be useful aids in CHF. This index predicts
functional dependency and mortality in CHF patients even
with a preserved ejection fraction [7].
2.2. The Clinical Problem. Data show that protein visceral
malnutrition impairment in patients with CHF is not always
as severe as muscle wasting. Very often, visceral protein
synthesis is also conserved. Indeed, skeletal muscle wasting
(measured by magnetic resonance spectroscopy) was found
in 68% of CHF patients, while up to 24% of patients had
serum albumin levels <3.5 g/dL [3]. This apparent discrep-
ancy can be explained by considering the metabolic role of
the amino acids (AA) of striate muscles. Indeed, we can
say that skeletal muscle is a pivotal organ, which maintains
body metabolic performance by the continuous exchange
of fuel with the liver. Under malnutrition, starvation,
and/or catabolic circulating stimuli, striate muscle protein is
degraded andAAare released into the blood.The releasedAA
are essential formaintaining global protein synthesis (includ-
ing albumin) and glucose plasma levels, through hepatic
gluconeogenesis and cell energetic metabolism. Indeed, AA
contain carbon, oxygen, hydrogen, and nitrogen. They can
therefore bemetabolized into carbohydrates (such as glucose)
or directly into lipids in accordance with the thermodynamic
status of the cell. It must be pointed out that lipids cannot
be transformed into carbohydrates by mammals. In addition,
AA are fundamental intermediaries for the tricarboxylic
acid cycle [8]. Clinically interesting, about 16% of patients
with muscular wasting progress to cachexia. However, this
phenomenon is related to a dramatic increase in mortality as
50% of cachectic patients die within 18 months [9, 10].
2.3. Why It Occurs. The genesis of visceral and muscular
proteins breakdown in CHF has not yet been completely
understood. The more accepted hypotheses indicate that
the catabolic effects of inflammatory cytokines (e.g., tumor
necrosis factors and interleukins) and neuroendocrine hor-
mones (catecholamines, cortisol, and renin) are responsible
for this phenomenon [11, 12].
Indeed, the increase in plasma catabolic molecules in
patients with CHF has been well documented. Recently,
impairment of anabolic hormones such as insulin with
insulin resistance (IR) has also been found in 58% of CHF
patients [13]. In muscles, the lack of anabolic stimulation due
to IR and the increase of catabolic stimuli causes protein
degradation and AA release.These AA are used in the liver to
produce glucose by gluconeogenesis. In addition, IR inhibits
mRNA synthesis of phosphoenol pyruvate carboxykinase
(the key enzyme of the gluconeogenesis pathway) in the liver.
This contributes to reducing gluconeogenesis further via
pyruvate originating from lactate. Thus, a vicious circle is
generated, where malnutrition does not supply exogenous
nutrients, the liver produces low quantities of carbohydrate
from alternative metabolic pathways, and muscle AA are
used to produce glucose essential to maintain the glucose-
dependent metabolism of fundamental structures such as the
brain and erythrocytes.
Moreover, under these conditions, muscle glycogen
reserves are depleted and free fatty acids (FFA) become the
principal fuel for the muscle. However, FFA use is a limiting
factor for energy production [14]. In fact, accumulation of
FFA in the myocytes reduces energy production during
exercisewith consequent skeletalmuscle fatigue [15].Notably,
insulin also plays an important role in regulating adipose
metabolism. Small increases in plasma insulin significantly
reduce lipolysis in adipose tissue. This insulin increase
reduces the availability of FFA for acetyl-CoA production,
which is fundamental for maintaining cell energy produc-
tion. Consequently, cell energy production via the anaerobic
metabolic pathway is maintained by acetate which is derived
predominantly from AA breakdown and oxidation. It is clear
that the availability of AA is a key factor in maintaining
mammal cell metabolism.
2.4. Possible New Therapeutic Approaches. In the light of
these findings, we can say that the alteration of protein
metabolism is clinically important. This could be due to
different conditions related to age and/or inflammatory
diseases, reduced qualitative/quantitative food intake, and/or
malabsorption. We believe that combined pharmacological
and nutritional interventions, such as personalized therapy
based on the specific needs of individual patients, can
maintain cell metabolism hence aiding traditional standard
therapy in CHF patients.
Data show that exogenous oral supplementation with a
special mixture of individual essential AA tailored for human
needs (EAAm) could be a valid therapeutic strategy to use in
patients with CHF, in combinationwith conventional therapy
to prevent protein malnutrition with protein wasting for the
following reasons.
Firstly, EAAm could resolve malnutrition related to
reduced nutrient gut absorption due to exocrine exhaustion
of the pancreas caused by CHF. It is well known that the
pancreas is the major consuming organ of AA. Furthermore,
the pancreas plays a fundamental role in fooddigestion.How-
ever, digestion and food absorption need adequate synthesis
and secretion of different enzymes.
This process uses enormous quantities of AA and energy
at all meals. In patients with CHF, the exocrine efficiency of
the pancreas is progressively reduced. As we have seen, this
then causes a vicious circle, lower digestion of proteins, and
lower availability of AA for digestive enzyme synthesis.
This condition leads to impaired digestion with a conse-
quent reduction of plasma patterns of AA which are insuf-
ficient to promote protein synthesis. Interestingly, single AA
are not digested. They are rapidly absorbed and immediately
available in the blood for protein synthesis [16].
Secondly, EAAm are positive signals for maintaining
muscle protein stores and so reducing IR. Indeed, AA inhibit
changes to glucose transport as well as gluconeogenesis
mediated by IR. In addition, at high physiological concen-
trations, AA activate various important phases of protein
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synthesis [17, 18]. Data show that AA are signals for the
secretion of IGF-1 and -2 (insulin-like growth factor-1 and -
2) [19]. IGF-1 is the somatomedin responsible for the main
activation of growth hormone (GH), an anabolic hormone
which promotes protein synthesis and counteracts IR.
Thirdly, EAAm modulate the effects of insulin on adipo-
cytes enhancing glucose-induced desensitization of insulin-
stimulated glucose transport and regulate the synthesis of
FFA [20]. In particular this effect is mediated by glutamine.
Finally, it has recently been demonstrated that EAAm,
including essential and branched ones as well as lysine,
can maintain protein synthesis, support energy needs, and
stimulate mitochondrial biogenesis [21].These effects are due
to the capability of AA to activate AMP-activated protein
kinase mammalian target of rapamycin (mTOR) and nitric
oxide synthase (NOS). These are important enzymes which
stimulate cell life and development (including stem and
endothelial cells), regulating energy production/use, protein
synthesis, cell proliferation, antiapoptotic processes, and
mitochondrial biogenesis [22, 23].
In addition to EAAm, other molecules have been inves-
tigated and are presently under investigation, as nutritional
support for CHF patients in order to understand their role in
avoiding protein disarrangement. A recent multicenter phase
III clinical trial demonstrated that Amalirin (orally active
ghrelin receptor antagonist) can reverse muscle wasting in
cancer cachexia and has been proposed as a therapeutic agent
for all stage of cachexia. The protein’s anabolism can also
be modulated by stimulation of selective androgen receptor
modulators (SARMs) in humans and by activating type II
receptor of Myostatin in both animal models and humans.
Another animal study showed that the anabolic/catabolic
transforming agent MT-102 reverses muscle wasting in rats
[24].
3. Gut Flora Dysbiosis
The mammalian gastrointestinal tract contains about 100
trillion microorganisms called gut flora or microbiota. This
is ten times greater than the total number of human cells
in the body. For this reason, it is also called “the forgotten
organ.” Microbiota benefits the host by exerting many
crucial functions for host life. Indeed, microbiota regulates
the guts’ barrier function and motion, influences nutrient
absorption, produces important metabolic intermediaries,
including vitamins, and modulates local and systemic
inflammation through innate immunity. Consequently, gut
microbiota influences the metabolism of tissues outside the
intestine.Thus, alterations of the composition and/or activity
of microbiota, known as dysbiosis, as well as intestinal
functions, influence the evolution of diseases independent
of the original cause of the disease. Recently, gut microbiota
dysbiosis has been proposed as an environmental factor
capable of causing a catabolic state with consequent muscle
wasting [25–27].
3.1. The Evidence. Recently, we demonstrated that CHF
patients had significant qualitative and quantitative impair-
ment of gut flora. Particularly, pathological species were
present in the majority of CHF patients. Indeed, we found
the massive presence of Candida, Campylobacter, Shigella,
Salmonella, and Yersinia in the stools of CHF patients. The
massive presence of this pathogenic contaminating flora had
important pathophysiological effects on patients with CHF,
because they significantly correlate with systemic inflamma-
tion and intestinal functions including permeability (authors’
unpublished data).
3.2. The Consequence. Research shows that there are molec-
ular reasons for the link between dysbiosis and systemic
catabolism. Indeed, pathogens produce lipopolysaccharide
(LPS) and other fungal or bacterial toxins which cause locally
produced cytokines with consequent intestinal epithelial
inflammation, which increases gut membrane permeability.
This intestinal endothelial dysfunction allows the translo-
cation of fungal or bacterial toxins from the gut to the
circulating blood. In turn, this increases both circulation
inflammatory molecules such as TNF-alfa and LPS. These
stimulate inflammatory cells to produce catabolic molecules
capable of causing muscular wasting, sarcopenia, and finally
cachexia [28–30].
Recently, researchers have identified the enzymatic activ-
ities of protein effectors injected into host cells by pathogens
such as Shigella, Salmonella, andYersinia.This occurs through
their type III secretion system, which modulates host innate
immune responses. Specifically, bacterial acetyl-transferase
modifies AA residues of cellular MAPK and I-KK-beta
modulating inflammatory cell response and activating intra-
cellular apoptosis [31]. The consequent state of chronic
inflammation has been well documented in CHF patients
and it is thought to be responsible for functional organs
dysfunction and clinical deterioration [28].
The anatomical and functional alteration of the ente-
rocytes induced by contaminating flora also influences the
intestinal nutrient absorption and gastrointestinal mobility
causing malnutrition.This aspect is particularly important in
CHF patients because it is well known thatmalnutrition, with
consequent muscular wasting and cachexia, is very common.
Various hypotheses can be formulated to explain the massive
presence of contaminating pathological microorganisms in
the gut flora. The more accredited hypotheses consider local
ischemia and indiscriminate antibiotic use as responsible
of pathogens overgrowth. Local ischemia is due to CHF-
mediated distribution of blood flow which underperfuses
gut endothelium. Ischemia causes intramucosal acidosis,
hypercapnia, and oxygen-free radical production. Moreover,
CHF patients have neuroendocrine activation with nore-
pinephrine increase. These conditions are all known to be
activators of bacterial virulence and can also influence patho-
logical bacteria overgrowth (authors’ unpublished data). The
overuse of antibiotics in the food chain may contribute to
selecting antibiotic resistant pathogens, which then colonizes
the intestine.
4. Therapies
Currently, there are no specific therapies to cure microbiota
dysbiosis available. However, encouraging data suggest that
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gut dysbiosis can be modified by several means such as nutri-
tional supplementation with specific nutrients (prebiotics)
and/or live bacteria (probiotics) and/or local therapies with
fecal microbiota transplant or colon hydrotherapy [32].
Fecal microbiota transplant (or stool transplant) is a pro-
cess of transplanting fecal bacteria from healthy individuals
into recipients. FMT involves restoring the colonicmicroflora
by introducing healthy bacterial flora through the infusion
of stools. Colon hydrotherapy is a technique which reduces
waste material in the colon by using tubes in order to insert
water, with or without specific therapy, into the colon via the
rectum with special equipment [32].
5. Conclusive Remarks
CHF is a complicated multifactor disease with important
social-economic impact. In spite of the recent development of
new drugs and therapeutic strategies, CHF-related mortality
and morbidity remain high. Recent evidence suggests that
changes in organs such as skeletalmuscle and gut flora play an
important and independent role in CHF prognosis. Specific
therapies need to be identified in the future in order to
maintain the metabolic and functional homeostasis of these
organs so that we can cure CHF patients better.
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